



Chemically Modified Antisense Oligonucleotides: Promising Tools for the Therapy of Diseases

Guest Editors:

Prof. Dr. Leonidas A. Phylactou

Chief Executive Officer and
Medical Director, The Cyprus
Institute of Neurology & Genetics,
PO Box 23462, Nicosia 1683,
Cyprus

Dr. Nikolas Mastrogiannopoulos

Department of Molecular
Genetics, Function and Therapy,
The Cyprus Institute of Neurology
& Genetics, PO Box 23462,
Nicosia 1683, Cyprus

Deadline for manuscript
submissions:

closed (28 February 2017)

Message from the Guest Editors

Dear Colleagues,

Antisense oligonucleotides (AONs) have been widely studied as regulators of gene expression by their direct interaction mainly with RNA or RNA regulating molecules. During the last 20 years, AONs have shown to have the potential to treat various diseases, such as cardiovascular diseases, diabetes, cancer, neurological diseases, and muscular dystrophies. Nevertheless, several drawbacks have been identified towards this way. Introduction of chemical modifications to AONs have shown to be beneficial in several cases, providing among other things, resistance to nucleases, stability, and increased target affinity.

I would like to welcome you to submit articles and reviews on chemically modified AONs against diseases.

Prof. Dr. Leonidas A. Phylactou
Dr. Nikolas Mastrogiannopoulos
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com